Algernon Health Stock Price, News & Analysis

Algernon Pharmaceuticals announced significant results from its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil), highlighting a 267 ng/L reduction in interleukin 6 (IL-6) levels in the 20 mg treatment group compared to 7 ng/L in the standard care group (p = 0.0292). This reduction indicates potential therapeutic implications for idiopathic pulmonary fibrosis (IPF) and chronic cough, as the company continues its Phase 2 trial targeting these conditions. Algernon has achieved 50% of its enrollment target for the IPF study, further measuring biomarkers such as C-reactive protein.

Algernon Pharmaceuticals has reached 50% enrollment for its Phase 2 clinical trial of NP-120 (Ifenprodil) targeting idiopathic pulmonary fibrosis (IPF) and chronic cough. The trial aims to evaluate Ifenprodil's efficacy in preserving lung function and reducing cough frequency in IPF patients. In preclinical studies, Ifenprodil demonstrated a 56% reduction in fibrosis and a 42% decrease in cough frequency. The IPF market is projected to grow significantly, from $900 million in 2015 to $3.2 billion by 2025, indicating potential market opportunities for the company.

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has filed an end of Phase 2 meeting request with the FDA following the completion of its Phase 2b clinical trial for NP-120 (Ifenprodil) in COVID-19. This meeting aims to discuss clinical trial design and assess the transition to Phase 3 with expedited responses expected due to the pandemic context. The company clarifies it does not claim Ifenprodil can treat or prevent COVID-19. Algernon focuses on repurposing existing drugs for new therapeutic applications.

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced plans to request an End-of-Phase 2 meeting with the FDA following the completion of its Phase 2b COVID-19 trial for NP-120 (Ifenprodil). The company aims to discuss trial data and seek guidance for a potential Phase 3 study. Initial data review has shown some negative dose effects at the 40mg level, with further analysis on key endpoints such as mortality and ICU time planned. Algernon aims to leverage the FDA's feedback to inform their next steps in the development process.

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) appointed Dr. Steven L. Wolf as a consultant for its clinical research program on AP-188 (DMT) for stroke treatment. Dr. Wolf is a renowned expert in Physical Therapy and Rehabilitation Medicine, with over 300 publications and significant contributions to improving stroke recovery methods. His expertise will guide the design of the Phase 2 clinical study assessing DMT's potential to aid neural recovery post-stroke, following promising results from animal studies. This collaboration may enhance Algernon's research capabilities.

Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF) announced topline data from its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil). Key findings revealed 0% mortality in the 20 mg Ifenprodil group at Day 15 versus 3.3% in the control group. Patients with low blood oxygen showed a return to normal levels more quickly in the treatment group. However, the WHO score showed no significant changes across study arms. The company plans to discuss results with the U.S. FDA and publish detailed data in a peer-reviewed journal.

Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced its inclusion in the Horizons Psychedelic Stock Index ETF in the first quarterly rebalance. This ETF offers investors exposure to North American companies engaged in psychedelic-related activities. CEO Christopher J. Moreau highlighted that this recognition reflects Algernon's significant progress in its DMT stroke research program. The company is investigating the use of DMT as a treatment for stroke and has filed provisional patents related to its formulations and methods.

Algernon Pharmaceuticals has filed a pre-IND meeting request with the U.S. FDA for its investigational drug AP-188 (DMT) targeting stroke-related dysfunction. This marks the start of formal communications regarding its stroke clinical research program. The application seeks FDA guidance on using DMT alongside constraint-induced movement therapy (CIMT) to enhance recovery in stroke patients. Positive preclinical studies indicate DMT promotes neurogenesis and motor recovery. Algernon also awarded contracts for DMT manufacturing and preclinical studies, with a focus on advancing stroke treatment.

Algernon Pharmaceuticals expects to report topline results from the Phase 2b part of its Phase 2b/3 COVID-19 trial of Ifenprodil in the last week of March 2021. This multinational study aims to evaluate Ifenprodil's safety and efficacy in hospitalized COVID-19 patients. The independent statisticians will review the data before public release. CEO Christopher J. Moreau emphasizes an urgent need for effective COVID-19 therapies. The trial's positive outcomes could lead to a Phase 3 trial with a larger patient cohort, aiding in the fight against severe COVID-19.